Archeal RadA, humanised to resemble RAD51, binds the fourth BRC repeat with high affinity.
Chimeric archeal/human RAD51 shows increased thermal stability.
Robust crystallographic system enables fragment-based drug discovery against RAD51.
Dedicated surrogate proteins were needed for different assays.